Am Fam Physician. 2019 Jul 15;100(2):74.
Incorrect FDA approval. The article, “Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment” (March 15, 2019, p. 362), contained an error in the last sentence of the “Anticoagulant Therapy” section in the first column of page 367, which stated that the combination of rivaroxaban (Xarelto) with aspirin had not been approved by the U.S. Food and Drug Administration (FDA) for use in patients with coronary artery disease or symptomatic peripheral artery disease. Although this statement was accurate when the article was submitted, in October 2018 the FDA issued an approval for the use of rivaroxaban in combination with aspirin “to reduce the risk of major cardiovascular events (cardiovascular [CV] death, myocardial infarction [MI] and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease.” Before publication, the article was not updated to reflect this approval. The sentence regarding lack of FDA approval has been removed.
Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions